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Abstract
People with chronic fatigue syndrome (CFS) suffer from multiple symptoms including fatigue,
impaired memory and concentration, unrefreshing sleep and musculoskeletal pain. The exact
causes of CFS are not known, but the symptom complex resembles that of several diseases that
affect the immune system and autoantibodies may provide clues to the various etiologies of CFS.
We used ELISA, immunoblot and commercially available assays to test serum from subjects
enrolled in a physician-based surveillance study conducted in Atlanta, Georgia and a population-
based study in Wichita, Kansas for a number of common autoantibodies and antibodies to neuron
specific antigens. Subsets of those with CFS had higher rates of antibodies to microtubule-
associated protein 2 (MAP2) (p = 0.03) and ssDNA (p = 0.04). There was no evidence of higher
rates for several common nuclear and cellular antigens in people with CFS. Autoantibodies to
specific host cell antigens may be a useful approach for identifying subsets of people with CFS,
identify biomarkers, and provide clues to CFS etiologies.
Background
Chronic fatigue syndrome (CFS) is defined as persistent or
relapsing fatigue that has occurred for at least 6 months, is
not alleviated by rest, and causes substantial reduction in
activities. The fatigue cannot be explained by medical or
psychiatric conditions and must be accompanied by at
least 4 of 8 specified symptoms (unusual post exertional
fatigue, impaired memory or concentration, unrefreshing
sleep, headaches, muscle pain, joint pain, sore throat, and
tender cervical nodes) [1]. There is considerable discrep-
ancy in results between studies from different institutions;
so as yet, there are no characteristic signs or laboratory
markers of CFS and its pathophysiology has not been elu-
cidated [2].
This lack of diagnostic signs or laboratory markers not-
withstanding, many manifestations of CFS resemble those
of musculoskeletal and infectious diseases [3]. In large
part, the illnesses caused by these diseases reflect immune
system activation and there is evidence for immune sys-
tem dysfunction in some cases of CFS. In particular, anti-
nuclear antibodies (ANA) and other common
autoantibodies have been evaluated in people with CFS:
unfortunately, with variable results. For example, one
study found that 52% of tertiary care- CFS referral-patients
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had antibodies to nuclear envelope antigens [4] while
another study found the same ANA antibody rates in both
CFS and controls [5]. Recently, investigators reported that
antibodies to the human muscarinic cholinergic receptor
1 may provide a biologic explanation for the cognitive
impairment observed in people with CFS [6]. This lack of
consensus between studies may in large-part reflect
recruitment bias associated with studies of persons
enrolled from tertiary referral clinics combined with
imprecise evaluation of the illness and inadequate or
inappropriate control populations.
We had the opportunity to measure the associations of
common autoantibodies and autoantibodies to neuronal
cell antigens and CFS in two case control studies; one of
primary care patients with CFS who were identified by a
physician surveillance network; the other a study of peo-
ple with CFS identified from the community. The physi-
cian surveillance study was conducted 1988 through 1993
in Atlanta, Georgia [7] and the community study 1997
through 2000 and identified subjects with CFS from the
general population of Wichita, Kansas [8].
Both studies rigorously classified people as CFS and con-
trols in both studies were enrolled to represent the general
population and matched to cases by sex, race, and age
[9,10]. The hypothesis of the present study is that the
appearance of cell-specific autoimmune antibodies may
define subsets of CFS and give clues to the etiology and
pathogenesis and may help to explain the neurocognitive
symptoms experienced by CFS patients. Secondarily, we
wished to evaluate the extent to which patients with CFS
who were receiving primary medical care treatment for
CFS were similar to people with CFS in the community.
Methods
Study Subjects and samples
Both studies adhered to human experimentation guide-
lines of the U.S. Department of Health and Human Serv-
ices and the Helsinki Declaration. The Centers for Disease
Control and Prevention (CDC) Institutional Review
Board approved study protocols. All participants were vol-
unteers who gave informed consent.
Physician surveillance study
Between 1988 and 1993, the CDC conducted a physician
surveillance survey for CFS in primary care patients from
Reno, Nevada, Wichita, Kansas, Grand Rapids, Michigan,
and Atlanta, Georgia [7]. Patients were classified as CFS
according to the 1988 case definition [11]. In 1992, we
conducted a case control study of CFS patients and con-
trols in Atlanta by recruiting patients from physician sur-
veillance and sex, race, age matched non fatigued controls
identified in the general Atlanta population [9,10]. The
case control study classified patients as CFS according to
the study collected information concerning several risk
factors and blood to measure associations between CFS
and laboratory markers. The present study used remaining
archived serum samples from 22 CFS patients and 34 age
and sex matched controls. All CFS patients met criteria of
the current CFS research case definition [1]
Population study participants
Between 1997 and 2000, CDC conducted surveillance of
CFS in the general population of Wichita, Kansas [8].
Briefly, the study involved random digit dial surveys to
identify people with CFS-like illness and clinically evalu-
ated and classified them according to criteria of the 1994
CFS research case definition [1]. Only 16% of those iden-
tified with CFS had been diagnosed or treated for CFS by
a physician [12]. The present study used archived serum
samples from 37 subjects with CFS and a 57 non-fatigued
control subjects
Blood samples
Both the physician surveillance and population study col-
lected blood in BD Vacutainer Serum tubes. The samples
were shipped by overnight courier to CDC where they
were dispensed into 0.5 ml aliquots and stored at -80°C
until testing.
Reagents and Assays
Commercially available kits were used for antibodies to
ubiquitous nuclear and cellular autoantigens including
dsDNA, ssDNA, Sm, U1-RNP, SS-A/Ro, SS-B/La, Scl-70,
and Centromere. Immunoassays were purchased from
Helix Diagnostics (West Sacramento, CA) and reagents for
western blots were purchased from Diagnostic Products
Corporation (Los Angeles, CA). Purified Histone H3, and
Histone H4 were purchased from Sigma (St. Louis, MO).
and used in ELISA assays that were developed at Scripps.
Conventional immunofluorescent antinuclear antibodies
and rheumatoid factor tests were performed as described
previously [13]. Preparations of microtubule-associated
protein 2 (MAP2) and neurofilament triplet (NFT) pro-
teins were purchased from Sigma (St. Louis, MO). The
commercially available ELISA assays were performed
according to the manufacturers instructions. The ELISA
and western blot assays for the neuronal antigens were
developed at Scripps and were performed as previously
described [14].
Statistical Analysis
Because the subjects are derived from studies that are dis-
tinct in design and geographic location, each study was
analyzed separately. The distribution of autoantibodies
between CFS and non-fatigued controls was compared by
Fisher exact probability test. To derive an estimate of con-
fidence, stratified groups were compared by the non-par-
ametric chi square test. To determine associations,Journal of Autoimmune Diseases 2005, 2:5 http://www.jautoimdis.com/content/2/1/5
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subjects were stratified by sex, age, and CFS for all MAP2,
NFT and ssDNA. The association of autoantibodes in CFS
subjects was compared by grouping by sex, age, age at ill-
ness onset, and duration of illness. CFS subjects were strat-
ified by sex, age (<40 years, 40–40 years, >50 years), onset
type (gradual versus sudden) and duration of illness (<5
years, >5 years) to determine whether an association with
autoantibodies existed.
Results
Although women predominated in both study groups
other demographic and clinical characteristics differed
and reflected basic differences between patients with CFS
who obtain medical care and those in the general popula-
tion (most of whom have not seen a physician) (Table 1).
Of note, CFS cases from physician surveillance were some-
what younger than those identified in the population
(mean 39 and 46 years, respectively) and controls were
similarly different: those recruited in the physician study
had been ill about half as long as those in the community
(69 and 128 months, respectively) and were more likely
to report sudden onset CFS (36.4%) than those in the gen-
eral population with CFS (13.5%).
A few CFS subjects in the physician surveillance study
aged 18–29 years had antibodies to ssDNA when com-
pared to the same age non-fatigued control group. The
mean value for the 3 CFS subjects was 2-fold greater then
in the 6 non-fatigued controls (p = 0.038). Among CFS
subjects, the 10 who reported being ill for ≤  5 years had
lower levels of autoantibodies to MAP2 (median value of
18, range 12 – 20) compared to the 12 CFS subjects who
have been ill for >5 years (median value of 8, range 6 to
10) (p = 0.025). There were no other significant findings
in the physician surveillance CFS subjects when stratified
by sex or type of illness onset.
In the population-based study, there was a significant dif-
ference in the prevalence of autoantibodies to MAP2
between the 30 male subjects (20/30, 67% positive) and
the 64 female subjects (19/64, 30% positive) (p =
0.0006). Among the non-fatigued control group, 9 of 33
women (27%) and 19 of 24 (79%) men were positive for
antibodies to MAP2 (p = 0.0004). One male CFS subject
(16%) was positive for MAP2 antibodies compared to
79% (19/24) male non-fatigued controls (p = 0.04).
Among CFS subjects that were ≤  40 years of age, there was
a trend for lower MAP2 antibody levels for those that were
ill for ≤  5 years compared to those ill for >5 years (p =
0.056).
Discussion
CFS is a complex, debilitating illness, which is character-
ized by at least 6 months of severe persistent or relapsing
fatigue and a group of characteristic but nonspecific symp-
toms. Despite more than a two decades of extensive
research, no diagnostic tests exist, and effective control
and prevention remain elusive because the cause and
pathophysiology of CFS remain unknown. CFS is clini-
cally similar to several rheumatic autoimmune disorders
that can be diagnosed and characterized by autoantibody
profiles. For this reason, we conducted an exhaustive eval-
uation of 11 ubiquitous nuclear and cellular autoantigens
in addition to two neuronal specific antigens.
The serum samples tested in this study were collected
from a physician surveillance study conducted in Atlanta
[15] and a population-based community study in Wichita
[8]. The physician surveillance study was conducted over
Table 1: Characteristics of subjects evaluated for 
autoantibodies.
CFS Non-Fatigued
Atlanta Case Control
Subjects (n = 56) 22 34
Female (n = 52) 19 33
Male (n = 4) 3 1
Age Group (yrs)
18–29 (n = 9) 3 6
30–39 (n = 18) 7 11
40–49 (n = 23) 12 11
50–59 (n = 6) 0 6
Mean Age 39 years 38 years
Mean Age Onset 35 years
Onset type
Sudden 8
Gradual 14
Mean Illness Duration 69 months
Number of Subjects Ill
< 5 years 10
>5 years 12
Wichita Population
Subjects (n = 94) 37 57
Female (n = 64) 31 33
Male (n = 30) 6 24
Age Group (yrs)
18–29 (n = 14) 1 13
30–39 (n = 18) 8 10
40–49 (n = 26) 13 13
50–69 (n = 36) 15 21
Mean Age 46 years 42 years
Mean Age Onset 36 years
Onset type
Sudden 5
Gradual 32
Mean Illness Duration 128 months
Number of Subjects Ill
< 5 years 14
>5 years 23Journal of Autoimmune Diseases 2005, 2:5 http://www.jautoimdis.com/content/2/1/5
Page 4 of 5
(page number not for citation purposes)
7 years and used approximately 70% of all primary care
physicians in Atlanta. All patients were carefully evaluated
for unexplained unwellness and fatigue. The community
study was a random digit dial survey of 90,000 people
(25% of the Wichita, Kansas population). All CFS cases
were medically and psychiatrically evaluated and rigor-
ously classified as CFS, other unexplained unwellness, or
medically/psychiatrically explained unwellness. The
serum evaluated in this study includes carefully evaluated
CFS subjects, matched controls and non-fatigued controls
from the community. Therefore, the results from this
study should be applicable to similarly designed studies.
Very few studies have evaluated the presence of autoanti-
bodies in people with CFS. Those that have tested for the
same autoantibodies report discordant results. Konstanti-
nov et al, [4] found high rates of antinuclear antibodies
(ANA) in CFS patients while Skowera et al, [5] found no
difference in the rate of ANA between CFS patients and
controls. One explanation for these discrepancies could
be a technical one where laboratories used different rea-
gents and methods resulting in discordant results.
Another explanation could be that the CFS subjects were
evaluated differently. Rigor in evaluating CFS patients and
applying the case definition [1] is pivotal and undoubt-
edly accounts for much of the variation. The results pre-
sented also show little evidence for autoantibodies to
ubiquitous nuclear and cellular autoantibodies.
The findings of this study hint that evaluation of certain
autoantibodies may give clues to etiology and ongoing
pathology in subsets of CFS subjects. A few of the physi-
cian surveillance CFS cases from the youngest age category
had autoantibodies to ssDNA. Autoantibodies to ssDNA
have been associated with both viral and bacterial infec-
tion [16,17]. Interestingly, CFS subjects who describe a
sudden onset to their illness often report flu-like illness.
The fact that antibodies to ssDNA were detected only in
this age group may reflect an immune response to infec-
tion commonly affecting this age group, such as infectious
mononucleosis from Epstein Barr Virus infection.
There was a higher prevalence of autoantibodies to MAP2
in the non-fatigued men in the community study com-
pared to the non-fatigued women. The significance of this
finding is not known but highlights the importance of
carefully stratifying and controlling for factors that could
affect interpretation of results. There did seem to be a
slight association of MAP2 autoantibodies with duration
of CFS illness. Among CFS subjects in both study popula-
tions, those who had been sick longer had higher rates of
autoantibodies than those that report shorter duration of
illness. MAP2 is a neuron specific cytoskeleton protein.
Autoantibodies to MAP2 have been demonstrated in
patients with neuropsychiatric systemic lupus erythema-
tosus [14]. While no lesions or loss of central nervous sys-
tem function is reported in people with CFS, loss of
memory, concentration and cognitive impairment are
common complaints. Future studies will attempt to asso-
ciate assessment of these parameters with the presence of
MAP2 autoantibodies.
Conclusion
There was no evidence of higher rates of the common
autoantibodies in people with CFS. However, certain sub-
sets of CFS subjects that had higher rates of antibodies to
microtubule-associated protein 2 (MAP2) and ssDNA.
Autoantibodies to specific host cell antigens may be a use-
ful approach to stratify CFS subjects and provide clues to
CFS etiologies.
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